VWR Proudly Sponsors the Start-Up Stadium at the BIO International Convention in Philadelphia
RADNOR, Pa., June 12, 2015 /PRNewswire/ -- VWR (NASDAQ: VWR), a leading global, independent provider of products, services and solutions to laboratory and production facilities, is proud to be the exclusive sponsor of the Start-Up Stadium at the BIO International Convention in Philadelphia. The Start-Up Stadium Is a newly created event designed to provide start-up companies with the opportunity to deliver their pitch to key members of the investment community, venture philanthropy groups, and BIO attendees. Investors will provide live feedback and judge the sessions for an exciting and interactive experience.
As part of its sponsorship, VWR selected promising start-ups to present their emerging company. VWR is proud to announce that the following organizations will be joining 25 other start-up organizations to present at the convention next week.
Ascendia Pharmaceuticals is a specialty pharmaceutical company dedicated to developing enhanced formulations of existing drug products as well as enabling formulations for pre-clinical and clinical stage drug candidates. The company is currently developing an injectable clopidogrel nano-emulsion for acute coronary syndrome and a cyclosporin opthalmic nano-emulsion for dry eye syndrome. Ascendia's technologies include nano-emulsions, amorphous solid dispersions and nanoparticles.
Ebelle D'Ebelle Pharmaceuticals, Inc., focused on the innovative development of quality, effective and affordable medicines for pediatrics, rare and neglected diseases, strives to develop clinically effective, stable, and easy to administer drugs and diagnostic tools for the treatment and diagnostic of debilitating medical conditions for those who needs them the most. The company's three lead, late stage products are for treatment of sickle cell anemia, transthyretin familial amyloid polyneuropathy (TTR-FAP), and neurocysticercosis (NCC).
InteguRx Therapeutics has developed a proprietary transdermal drug delivery, a technology platform capable of achieving extraordinarily robust (>400x) enhancement of human skin permeation for a variety of drugs, via either patch or patch-free gel. The company's lead product delivers the anti-nauseant ondansetron in therapeutic quantities via once-daily application of a small quantity (~250 microliters) of gel, which is being developed for the treatment of pregnancy-induced nausea and vomiting.
LytPhage is a start-up biotech company in the Philadelphia area developing therapeutics to treat the critical medical needs of antibiotic resistant bacteria by using bacterial virus (phage) technology licensed from the laboratory of Dr. Roy Stevens, Temple University.
VIRAZE is an emerging biotech company utilizing a patented high throughput screening (HTS) technology to discover and develop small molecules with antiviral activity to treat viral diseases. The initial emphasis is on viral diseases that have unsatisfactory treatment options, with a lead program (VIR001) for the first approved drug to treat molluscum contagiosum (MC).
"Start-up organizations like these develop new technologies, discover cures and accelerate diagnosis," stated Mark McLoughlin, VWR's SVP and President of the Americas Lab and Distribution Services. "We are proud to sponsor this event as a way to help these organizations as well as the biotech industry."
VWR supports BIO throughout the year, both locally and nationally, by providing its members with product and service solutions that help stretch their lab budgets to support the growth of these organizations as they heal, fuel and feed the world.
About VWR
VWR (NASDAQ: VWR), headquartered in Radnor, Pennsylvania, is a leading, global, independent provider of products, services and solutions to laboratory and production facilities. With sales in excess of $4.3 billion in 2014, VWR enables science for customers in the pharmaceutical, biotechnology, industrial, education, government and healthcare industries. With more than 160 years of experience, VWR has cultivated a value proposition delivering product choice, operational excellence and differentiated services to improve our customers' productivity from research to production. VWR's differentiated services provide innovative, flexible and customized solutions from scientific research services to custom-manufactured chemical blends. Our dedicated team of more than 8,500 associates is focused on supporting scientists, medical professionals and production engineers to achieve their goals.
For more information on VWR please visit www.vwr.com.
Logo - http://photos.prnewswire.com/prnh/20101109/NY97837LOGO
SOURCE VWR
Share this article